A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Manier, Salomon; Lambert, Jerome; Macro, Magaret; Chalopin, Thomas; Dib, Mamoun; Rumpler, Anne; Gay, Julie; Bastie, Jean-Noel; Jacquet, Caroline; Sonntag Mottier, Cecile; Vincent, Laure; Perrot, Aurore; Mariette, Clara; Montes, Lydia; Rigaudeau, Sophie; Bigot, Noemie; Doyle, Margaret; Santra, Diptendu; Smirnov, Pavel; Albrecht, Claire; Touzeau, Cyrille; Corre, Jill; Moreau, Philippe; Avet-Loiseau, Herve; Hulin, Cyrille; Leleu, Xavier; Facon, Thierry

doi:10.1182/blood-2025-367

Public

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Shared by NobleBlocks on Nov 3, 2025 • 12:00 AM UTC

Authors:

Salomon Manier

Jerome Lambert

Magaret Macro

Abstract

Abstract Background. Teclistamab is a subcutaneous bispecific IgG4 antibody targeting BCMA on myeloma cells and CD3 on T cells, enabling T-cell–mediated cytotoxicity. Daratumumab is an anti-CD38 monoclonal antibody used in combination with standard agents. The current standard-of-care regimens in el...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!